Long-term cost and life-expectancy consequences of hypertension

Journal of Hypertension

Volumn 16, Issue 8, 1998, Pages 1103-1112

  Kiiskinen, Urpo ^a   Vartiainen, Erkki ^a   Puska, Pekka ^a   Aromaa, Arpo ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Costs; Hypertension; Life expectancy

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ABSENTEEISM; ADULT; ARTICLE; DIASTOLIC BLOOD PRESSURE; DISABILITY; DISEASE SEVERITY; DRUG COST; DRUG USE; FEMALE; FINLAND; FOLLOW UP; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; LIFE EXPECTANCY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PRODUCTIVITY;

EID: 0031824486     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816080-00004     Document Type: Article

References (27)

1. Weinstein MC, Stason WB. Hypertension - a policy perspective. Cambridge, MA: Harvard University Press; 1976.
2. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296:732-739.
3. Nissinen A, Tuomilehto J, Kottke TE, Puska P. Cost-effectiveness of the North Karelia hypertension program 1972-1977. Med Care 1986; 24:767-780.
4. Kawachi I, Malcom LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991; 9:199-208.
5. Johannesson M. The impact of age on the cost effectiveness of hypertension treatment: an analysis of randomized drug trials. Med Decision Making 1994; 14:236-244.
6. Jönsson BG. Cost-benefit of treating hypertension. J Hypertens 1994; 12 (suppl 10):S65-S70.
7. Johannesson M, Agewall S, Hartford M, Hedner T, Fagerberg B. The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men. J Intern Med 1995; 237:19-26.
8. Rovira J, Badia X, Pardell H. Cost of hypertension in Spain. J Hum Hypertens 1992; 6:481-483.
9. Schauffler HH, D'Agostino RB, Kannel WB. Risk for cardiovascular disease in the elderly and associated Medicare costs: the Framingham study. Am J Prev Med 1993; 9:146-154.
10. Johannesson M, Dahlof B, Lindholm LH, Ekbom T, Hansson L, Oden A et al. The cost-effectiveness of treating hypertension in elderly people - an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med 1993; 234:317-323
11. McMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J. et al. Blood pressure, stroke, and coronary heart disease - part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
12. Collins R, Peto R, McMahon S, Hebert P. Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease - part 2. short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335:827-838.
13. Fletcher A. Economics of hypertension control: a statement by the World Hypertension League. J Hum Hypertens 1994; 8:789-795.
14. Puska P, Tuomilehto J, Nissinen A. Vartiainen E (editors). The North Karelia Project - 20 year results and experiences. Helsinki: The National Public Health Institute (KTL); 1995.
15. Statistical Yearbook of the Social Insurance Institution. Helsinki: the Social Insurance Institution. 1996. p. T1:31.
16. Campbell MJ, Machin D. Medical statistics - a commonsense approach. Chichester: John Wiley & Sons; 1993
17. Rice DP, Estimating the cost of illness. Washington: Government Printing Office; 1966.
18. Hodgson TA. Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Q 1982; 60:429-462.
19. Ginzberg G, Blau H, Kerem E, Springer C, Kerem B-S, Akstein E, et al. Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population. Health Econ 1994; 3:5-23.
20. Statistics Finland. Consumer price index. Helsinki: Statistics Finland.
21. Stevens RD, Bingley LJ Jr, Boger M, El-Wanni J, Kaston J. Variability in the management of hypertension and cost effectiveness: methodology. community care results and potential cost reductions. Soc Sci Med 1984; 18:767-774.
22. Schelling TC. The life you save may be your own. In: Chase SB Jr (editor): Problems in public expenditure. Washington: Brookings Institution; 1968. pp. 127-176.
23. Mishan EJ. Evaluation of life and limb: a theoretical approach. J Political Economy 1971; 79:687-705.
24. Shiell A. Donaldson C, Gerard K. Cost of illness studies: an aid to decision making? Health Policy 1987; 8:317-323.
25. Koopmanschap MA. van Ineveld MB. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34:1005-1010.
26. Koopmanschap MA, Rutten FFH, van Ineveld MB, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Economics 1995; 14:171-189.
27. Jones-Lee MW, The value of transport safety. Oxford Rev Economic Policy 1990; 6:39-60.